Financial Report
FINANCIAL REPORT Interim financial report prepared in accordance with PRC accounting standards and systems (page 15 to 27) Notes to the interim financial report (prepared in accordance with PRC accounting standards and systems) Condensed interim financial report prepared in accordance with HKSSAP 25(page 66 to 77) 17 Prepared in accordance with PRC Accounting Standards and Systems (Unaudited) CONSOLIDATED BALANCE SHEET As at 30 th June 2003 Appendix I Prepared by: Guangzhou Pharmaceutical Company Limited Assets Notes Ending balance Opening balance Rmb Rmb Current assets: Cash VI-1 892,142,916.49 1,019,903,178.95 Short term investment VI-2 50,464,244.58 61,194,385.90 Notes receivable VI-3 16,152,920.93 180,000.00 Dividend receivable VI-4 2,359,954.92 5,474,684.92 Interest receivable —— Accounts receivable VI-5 1,009,479,818.74 716,482,532.62 Other receivable VI-6 167,803,876.13 122,975,499.77 Advance to suppliers VI-7 46,510,961.28 80,700,451.50 Subsidy receivable VI-8 10,042,998.97 10,064,712.63 Inventories VI-9 862,206,587.39 848,519,074.31 Prepaid expenses VI-10 87,602,721.92 81,727,619.19 Long-term debentures investments due within one year —— Other current assets —— Total current assets 3,144,767,001.35 2,947,222,139.79 Long-term investment Long-term equity investment VI-11 86,016,292.53 86,789,969.55 Long-term debentures investment — — Total long-term investment 86,016,292.53 86,789,969.55 Fixed assets Fixed assets - cost VI-12 1,418,286,389.49 1,247,479,589.50 Less: accumulated depreciation VI-12 465,261,433.47 442,207,260.76 Fixed
[Show full text]